Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.
Fiserv Reports ‘Strong First Quarter Results,’ Raises Full-Year Outlook
Fiserv Inc (FI) reported Q1 results, with revenue up 7% Y/Y to $4.88B, beating consensus of $4.57B. Adjusted EPS of $1.88 beat consensus of $1.79. Organic revenue grew 20%. FY24 outlook raised for adjusted EPS to $8.60-$8.75. FI stock gained 27% in last 12 months.
